GALT · Galectin Therapeutics Inc
$3.44
-0.09 (-2.55%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$346.92M
Shares
100.85M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2020-05-11 | — | $40,000,000 | — | — | 10-Q , filed 2025-11-14 |
Key facts
CIK
1133416
CUSIP
363225202
13F (30d)
99 filings
97 filers
Visit website
Investor relations